Clinical trials: Antimicrobial Resistance
- Condition Antimicrobial Resistance
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Bacterial Infections
New Antibiotic to Treat Pediatric Patients With Infections Due to a Specific Bacteria (Vancomycin-Resistant Enterococcus)
This study will treat pediatric patients who have infections that are due to a specific bacteria (Vancomycin-Resistant Enterococcus)
- Trial name
- NCT00035854
- Testing
- Zyvox® / Linezolid
- Where
- 21 sites in United States
- Volunteers
- 13 people
- Sponsor
- Pfizer
Bacterial Infections
Children's Antibiotic Resistant Infections in Low Income Countries
The main challenge of the ChARLI program is to assess the clinical burden of severe neonatal and childhood bacterial infections in low-income countries,in particular those caused by antibiotic resistant bacteria.
- Trial name
- ChARLI (NCT02074865)
- Testing
- biological samples
- Where
- Madagascar
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
Bacterial Skin Diseases
Multicenter Study of Antimicrobial Resistance of Gram-positive and Gram-negative Clinical Strains to Ceftaroline and Other Antimicrobials in Russia
Approximately 3,000 of clinically significant isolates of different species from respective respective sources in geographically distinct Russian cities will be collected and tested on ceftaroline and other antimicrobials.
- Trial name
- CERBERUS (NCT01700842)
- Where
- 2 sites in Russia
- Volunteers
- 3,000 people
- Sponsor
- AstraZeneca
Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Endocarditis
Direct Lysis of Staph Aureus Resistant Pathogen Trial of Exebacase
The purpose of this superiority study is to evaluate the efficacy and safety of exebacase in addition to standard of care antibiotics (SoCA) compared with SoCA alone for the treatment of patients with Staphylococcus aureus (S.
- Trial name
- DISRUPT (NCT04160468)
- Testing
- Exebacase
- Where
- 55 sites in United States
- Volunteers
- 259 people
- Sponsor
- ContraFect
Bacterial Infections
Study Evaluating the Association of Antibiotic Measures and Control of Bacterial Resistance
Assess efficacy of piperacillin/tazobactam in reducing the cases of colonization and infection of bacteria.
- Trial name
- NCT01788449
- Volunteers
- 335 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Blood Stream Infection, Blood Stream Infections
Evaluation of Diagnostic Accuracy and Clinical Performance of the UllCORE Bloodstream Infection (BSI) Test
This study is designed to evaluate the clinical performance of the UllCORE Bloodstream Infection (BSI) Test, an investigational molecular diagnostic test intended to detect microorganisms and selected antimicrobial resistance…
- Conditions
- Blood Stream Infection, Blood Stream Infections, Sepsis, Fungemia
- Trial name
- B-RAPID (NCT07859852)
- Testing
- UllCORE BSI Test
- Where
- 20 sites in United States, France and 3 more
- Volunteers
- 1,500 people
- Sponsor
- Deepull Diagnostics S.L.
Pneumonia, Pneumococcal, Community Acquired Infections
New Antibiotic to Treat Patients With Community-acquired Pneumonia Due to a Specific Bacteria (S. Pneumoniae Pneumonia)
This study will treat patients who have a community-acquired pneumonia that is due to a specific bacteria (S. pneumoniae)
- Conditions
- Pneumonia, Pneumococcal, Community Acquired Infections, Gram-positive Bacterial Infections
- Trial name
- NCT00035269
- Testing
- Antibiotic
- Where
- 46 sites in United States, Slovakia and 2 more
- Volunteers
- 230 people
- Sponsor
- Pfizer
Drug Resistance, Bacterial, Antimicrobial Drug Resistance
Fecal Microbiota Transplantation (FMT) to Decolonize Antibiotic - Resistant Bacteria (ARB) - New Protocol
The aim of the study is to assess the safety and efficacy of new protocol fecal microbiota transplantation (FMT) in the eradication of antibiotic resistant bacteria, including those featuring of resistance to new generation…
- Trial name
- STOP-ARB2 (NCT06156956)
- Testing
- Fecal Microbiota Transplantation
- Where
- 5 sites in Poland
- Volunteers
- 200 people
- Sponsor
- Human Biome S.A.
Infection
Study Evaluating Local Susceptibility Patterns Associated With Tigecycline in Comparison to Other Antibiotics
Various bacterial organisms will be tested in order to compile information regarding the effectiveness of tigecycline against certain bacteria seen in local communities.
- Trial name
- NCT01311349
- Volunteers
- 1,575 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer